Cargando…
Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724764/ https://www.ncbi.nlm.nih.gov/pubmed/36483732 http://dx.doi.org/10.3389/fphar.2022.1092147 |
| _version_ | 1784844485289574400 |
|---|---|
| author | Frontiers Production Office, |
| author_facet | Frontiers Production Office, |
| author_sort | Frontiers Production Office, |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9724764 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97247642022-12-07 Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab Frontiers Production Office, Front Pharmacol Pharmacology Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9724764/ /pubmed/36483732 http://dx.doi.org/10.3389/fphar.2022.1092147 Text en Copyright © 2022 Frontiers Production Office. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Pharmacology Frontiers Production Office, Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab |
| title | Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab |
| title_full | Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab |
| title_fullStr | Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab |
| title_full_unstemmed | Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab |
| title_short | Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab |
| title_sort | erratum: efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab |
| topic | Pharmacology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724764/ https://www.ncbi.nlm.nih.gov/pubmed/36483732 http://dx.doi.org/10.3389/fphar.2022.1092147 |
| work_keys_str_mv | AT frontiersproductionoffice erratumefficacyandsafetyevaluationsofanlotinibinpatientswithadvancednonsmallcelllungcancertreatedwithbevacizumab |